aCCI‐HBV‐ACLF: A Novel Predictive Model for Hepatitis B Virus‐Related Acute‐On‐Chronic Liver Failure

Xinyi Chen,Feiqiong Gao,Qiaoling Pan,Chenjie Huang,Rui Luo,Xiaoqing Lu,Xiaoxiao Chen,Tan Li,Haijun Huang,Jian Wu,Jiong Yu,Lanjuan Li,Hongcui Cao

DOI: https://doi.org/10.1111/apt.18347

IF: 9.524

2024-10-27

Alimentary Pharmacology & Therapeutics

Abstract:Elevated age‐adjusted Charlson comorbidity index (aCCI) is an independent risk factor for death in HBV‐ACLF patients. The new prediction model (aCCI‐HBV‐ACLF) exhibits excellent predictive accuracy for both 28−/90‐day mortality in patients with HBV‐ACLF compared with other established scoring systems. Background Early identification of hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF) holds crucial importance in guiding clinical management and reducing mortality. However, existing scoring systems often overlook patient's underlying clinical condition, which significantly impacts prognosis. Aims Use the age‐adjusted Charlson comorbidity index (aCCI) to evaluate the patient's complications to develop a more precise model for predicting transplant‐free mortality in HBV‐ACLF patients. Methods Nine hundred and six patients were included for investigation and were segregated into a training cohort and a temporal validation cohort according to the chronological order of admission in a ratio of 7:3. In the training cohort, univariate analysis, logistic regression analysis and LASSO regression analysis were used to construct a prognostic model and it was subsequently validated in a temporal validation cohort and an external validation cohort. Results We found total bilirubin, neutrophils, international normalised ratio and aCCI exhibited significant associations with 28‐day transplant‐free mortality and established a novel prognostic model, named aCCI‐HBV‐ACLF. The model demonstrated strong predictive performance, with area under the receiver operating characteristic curve (ROC) values of 0.859 for 28‐day mortality, 0.822 for 90‐day mortality. In the temporal validation cohort, aCCI‐HBV‐ACLF achieved area under the ROC values of 0.869 for 28‐day mortality and 0.850 for 90‐day mortality. In the external validation cohort, aCCI‐HBV‐ACLF had area under the ROC values of 0.868 for 28‐day mortality and 0.888 for 90‐day mortality. Conclusions This study proposes a new prognostic model, which achieved excellent predictive ability for 28−/90‐day transplant‐free mortality rates among patients with HBV‐ACLF.

pharmacology & pharmacy,gastroenterology & hepatology